PharmPK Discussion - How do we use models

• On 8 Jul 2015 at 09:44:21, Roger Jelliffe (jelliffe.-a-.usc.edu) sent the message
  

  
  What does one DO with Modeling and Simulation? Models are made to be USED clinically, for patients,
  not just for presentations, and this is the blind spot in the industry. What do we do all this stuff
  for? How do we USE these models? This is essentially not discussed in most PK/PD books I know. It
  would be SO refreshing to see it.
  Very best to all,
  Roger Jelliffe
  
  

  Back to the Top

• On 8 Jul 2015 at 12:40:46, William Wolowich (wwolowic.-a-.nova.edu) sent the message
  

  
  Antibiotic stewardship using monte-carlo simulation - the infectious disease folks have it figured
  out...it is changing patient care.
  
  

  Back to the Top

• On 9 Jul 2015 at 16:09:13, David Turner (David.Turner.at.certara.com) sent the message
  

  
  Hi
  
  Some of them are used like this:
  
  http://www.fda.gov/Drugs/NewsEvents/ucm387698.htm
  
  See recording links
  
  David Turner (Simcyp)
  
  

  Back to the Top

• On 9 Jul 2015 at 16:10:02, j.aaa.bulitta.com sent the message
  

  
  Dear William,
  
  I certainly share your enthusiasm about mathematical models in infectious diseases. And there is no
  doubt that Monte Carlo simulations have had a substantial benefit for selecting empirical doses of
  anti-infectives, accounting for covariate effects (e.g. renal function, critical illness, obesity),
  and drug development.
  I believe that there will be many addition benefits of mechanism-based and empirical models in
  infectious diseases for applications such as:
  Individualize doses by use of a PK/PD model instead of a target concentration
  Target site concentration modelling (most Monte Carlo sims are currently based on plasma)
  Translation from drug discovery, early/late in vitro, animal infection models, to human clinical
  trials and ultimately patients.
  Individualizing therapy for specific resistance mechanisms (integration with molecular diagnosis)
  Optimizing combination chemotherapy for normal and special patient populations
  Interactions between PK/PD models and the immune system
  Integration of PK/PD models with economic and public health models.
  
  So the field has made great progress, but there are still many fruits to earn. The list above can
  certainly be extended.
  
  Kind regards
  Juergen
  
  Juergen Bulitta, PhD
  
  

  Back to the Top

• On 9 Jul 2015 at 16:10:46, Michael Jones (michael.jones1211.aaa.gmail.com) sent the message
  

  
  William,
  Do you have a good reference for using monte-carlo simulation for antibiotic stewardship?
  Thanks,
  Michael A. Jones, PharmD
  Los Lunas, NM
  
  

  Back to the Top

Copyright 1995-2014 David W. A. Bourne (david@boomer.org)